Original Title: Ceftazidime/avibactam en infecciones severas

Authors' recommendations: CONCLUSIONS High-quality evidence shows that the ceftazidime/avibactam combination is non-inferior in terms of clinical response to its comparators, generally from the carbapenem class, for the treatment of severe intraabdominal infections, complicated urinary tract infections and nosocomial pneumonias due to Gram negative germs. There is higher uncertainty in other outcomes such as mortality; consequently it is not possible to confirm its non-inferiority in relation to its comparators. Low-quality evidence suggests that this combination, when compared with other antibiotic therapies such as colistin, might be useful for the treatment of bacteremias due to Gram negative germs and in severe infections caused by carbapenemase-producing Klebsiella pneumoniae. Most clinical practice guidelines consulted recommend this technology as an alternative for all the above mentioned indications. Most coverage policies consulted from the United States and Europe public and private sponsors do not mention this technology even though some of them cover it, especially in intraabdominal infections and complicated urinary tract infections. The coverage policies from Latin America consulted do not mention it. In order to include it, its high-cost in relation to its comparators should be taken into account.

Project Status: Completed

Year Published: 2018

URL for published report: https://www.iecs.org.ar/home-ets/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Argentina

Organisation Name: Institute for Clinical Effectiveness and Health Policy

Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA

Contact Name: info@iecs.org.ar

Contact Email: info@iecs.org.ar

Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)